Chronic Kidney Disease Collection
 1-18 of 18 Articles
ACP Journal Club |  16 February 2016
Review: More- vs less-intensive BP-lowering regimens reduce major CV events
Saurav Chatterjee, MD; Partha Sardar, MD; Anasua Chakraborty, MD; et al.
Ann Intern Med. 2016;164(4):JC14. doi:10.7326/ACPJC-2016-164-4-014
ACP Journal Club |  21 April 2015
In type 2 diabetes, saxagliptin increased HF hospitalizations, regardless of history of HF or CKD
Danae A. Delivanis, MD; Victor M. Montori, MD, MSc
Ann Intern Med. 2015;162(8):JC11. doi:10.7326/ACPJC-2015-162-8-011
ACP Journal Club |  18 November 2014
Review: In AF with CKD, novel oral anticoagulants reduce stroke or systemic embolism compared with warfarin
Thomas DeLoughery, MD, FACP, FAWM
Ann Intern Med. 2014;161(10):JC4. doi:10.7326/0003-4819-161-10-201411180-02004
ACP Journal Club |  16 September 2014
Review: In CKD, novel oral anticoagulants do not differ from vitamin K antagonists for efficacy or bleeding
Wolfgang C. Winkelmayer, MD, ScD
Ann Intern Med. 2014;161(6):JC10. doi:10.7326/0003-4819-161-6-201409160-02010
ACP Journal Club |  20 May 2014
Live kidney donation was associated with increased mortality and end-stage renal disease at 15 years
Amit X. Garg, MD, PhD; Neil Boudville, MD
Ann Intern Med. 2014;160(10):JC12. doi:10.7326/0003-4819-160-10-201405200-02012
ACP Journal Club |  19 November 2013
Review: Non–calcium-based phosphate binders reduce mortality compared with calcium-based binders in CKD
Chirag R. Parikh, MD, PhD
Ann Intern Med. 2013;159(10):JC2. doi:10.7326/0003-4819-159-10-201311190-02002
ACP Journal Club |  19 March 2013
Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs
Peter W. de Leeuw, MD
Ann Intern Med. 2013;158(6):JC7. doi:10.7326/0003-4819-158-6-201303190-02007
ACP Journal Club |  20 November 2012
Review: Statins decrease mortality and major CV events in adults with CKD not receiving dialysis
G. V. Ramesh Prasad, MBBS, FRCPC
Ann Intern Med. 2012;157(10):JC5-4. doi:10.7326/0003-4819-157-10-201211200-02004
ACP Journal Club |  20 November 2012
Review: Lipid-lowering drugs decrease all-cause and cardiac mortality and CV events in CKD
G. V. Ramesh Prasad, MBBS, FRCPC
Ann Intern Med. 2012;157(10):JC5-5. doi:10.7326/0003-4819-157-10-201211200-02005
ACP Journal Club |  20 November 2012
Review: Intensive glucose control reduces surrogate, but not clinical, renal outcomes in type 2 diabetes
Eugene C. Corbett Jr., MD, MACP
Ann Intern Med. 2012;157(10):JC5-6. doi:10.7326/0003-4819-157-10-201211200-02006
ACP Journal Club |  20 November 2012
CKD-EPI eGFR categories were better than MDRD categories for predicting mortality in a range of populations
Chi-yuan Hsu, MD, MSc
Ann Intern Med. 2012;157(10):JC5-12. doi:10.7326/0003-4819-157-10-201211200-02012
ACP Journal Club |  21 August 2012
Review: Antiplatelet therapy does not reduce mortality in chronic kidney disease
Bernard G. Jaar, MD, MPH
Ann Intern Med. 2012;157(4):JC2-8. doi:10.7326/0003-4819-157-4-201208210-02008
ACP Journal Club |  20 December 2011
Young adults with persistent, asymptomatic, isolated microscopic hematuria were at increased risk for ESRD
Donald A. Molony, MD
Ann Intern Med. 2011;155(12):JC6-12. doi:10.7326/0003-4819-155-12-201112200-02012
ACP Journal Club |  15 November 2011
Simvastatin plus ezetimibe reduced major atherosclerotic events in patients with chronic kidney disease
Maurice Laville, MD
Ann Intern Med. 2011;155(10):JC5-2. doi:10.7326/0003-4819-155-10-201111150-02002
ACP Journal Club |  16 November 2010
Early and late initiation of dialysis did not differ for reduction of all-cause mortality in stage 5 chronic kidney disease
Michael Walsh, MD, MSc
Ann Intern Med. 2010;153(10):JC5-2. doi:10.7326/0003-4819-153-10-201011160-02002
ACP Journal Club |  16 November 2010
Review: Erythropoiesis-stimulating agents targeted to higher hemoglobin levels increase risk for adverse outcomes in CKD
Chi-yuan Hsu, MD, MSc
Ann Intern Med. 2010;153(10):JC5-3. doi:10.7326/0003-4819-153-10-201011160-02003
ACP Journal Club |  16 April 2010
Review: Insufficient evidence exists on the benefit of vitamin D in patients with chronic kidney disease not requiring dialysis
James B. Wetmore, MD
Ann Intern Med. 2010;152(8):JC4-12. doi:10.7326/0003-4819-152-8-201004200-02012
ACP Journal Club |  16 March 2010
Darbepoetin decreased transfusions and fatigue, but increased adverse effects in patients with chronic kidney disease, diabetes, and anemia
Tejas V. Patel, MD, MPH, FACP, FASN
Ann Intern Med. 2010;152(6):JC3-9. doi:10.7326/0003-4819-152-6-201003160-02009
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.